Impact of pneumonia on hospitalizations due to acute exacerbations of COPD

Clinical Respiratory Journal

Volumn 8, Issue 1, 2014, Pages 93-99

  Andreassen, Siw Lillevik ^a   Liaaen, Erik Dyb ^b   Stenfors, Nikolai ^c   Henriksen, Anne H ^a,d  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b Aalesund Hospital   (Norway)

^c UMEÅ UNIVERSITY   (Sweden)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

COPD; Exacerbations; Hospitalizations; NIV; Pneumonia

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN;

ANTIBIOTIC THERAPY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE SEVERITY; FEMALE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONINVASIVE VENTILATION; OXYGEN THERAPY; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TEMPERATURE; THORAX RADIOGRAPHY; VERY ELDERLY;

COPD; EXACERBATIONS; HOSPITALIZATIONS; NIV; PNEUMONIA;

AGED; COMORBIDITY; DISEASE PROGRESSION; FEMALE; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; LENGTH OF STAY; LOGISTIC MODELS; MALE; NONINVASIVE VENTILATION; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES;

EID: 84891826957     PISSN: 17526981     EISSN: 1752699X     Source Type: Journal    
DOI: 10.1111/crj.12043     Document Type: Article

References (22)

1. Buist AS, McBurnie MA, Vollmer WM, etal. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007;370(9589): 741-750.
2. Lofdahl K, Strom K. Increasing morbidity and mortality in women with COPD. Lakartidningen. 2007;104(13): 1040-1042.
3. Lieberman D, Gelfer Y, Varshavsky R, Dvoskin B, Leinonen M, Friedman MG. Pneumonic vs nonpneumonic acute exacerbations of COPD. Chest. 2002;122(4): 1264-1270.
4. Royal College of Physicians BTS, British Lung Foundation. Report of the National Chronic Obstructive Pulmoary Disease Audit 2008: Clinical Audit of COPD Exacerbations Admitted to Acute NHS Trusts across the UK. London, Royal College of Physicians, 2008.
5. Lim WS, Macfarlane JT, Boswell TC, Harrison TG, Rose D, Leinonen M, Saikku P. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax. 2001;56(4): 296-301.
6. British Thoracic Society Pneumonia Guidelines Committee. Guidelines for the management of community acquired pneumonia in adults: update 2009; 2009. Report No. 1468-3296.
7. Molinos L, Clemente MG, Miranda B, Alvarez C, del Busto B, Cocina BR, Alvarez F, Gorostidi J, Oreajas C, ASTRURPAR group. Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease. J Infect. 2009;58(6): 417-424.
8. Steer J, Norman EM, Afolabi OA, Gibson GJ, Bourke SC. Dyspnoea severity and pneumonia as predictors of in-hospital mortality and early readmission in acute exacerbations of COPD. Thorax. 2012;67(2): 117-121.
9. Liaaen ED, Henriksen AH, Stenfors N. A Scandinavian audit of hospitalizations for chronic obstructive pulmonary disease. Respir Med. 2010;104(9): 1304-1309.
10. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106(2): 196-204.
11. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Global strategy for diagnosis, management, and prevention of COPD. Available at: http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html (accessed 12 August 2013).
12. Benfield T, Lange P, Vestbo J. COPD stage and risk of hospitalization for infectious disease. Chest. 2008;134(1): 46-53.
13. Clyne B, Olshaker JS. The C-reactive protein. J Emerg Med. 1999;17(6): 1019-1025.
14. Smith RP, Lipworth BJ, Cree IA, Spiers EM, Winter JH. C-reactive protein. A clinical marker in community-acquired pneumonia. Chest. 1995;108(5): 1288-1291.
15. Almirall J, Bolibar I, Toran P, Pera G, Boquet X, Balanzo X, Sauca G, Community-Acquired Pneumonia Marasme Study Group. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest. 2004;125(4): 1335-1342.
16. Flanders SA, Stein J, Shochat G, Sellers K, Holland M, Maselli J, Drew WL, Reingold AL, Gonzales R. Performance of a bedside C-reactive protein test in the diagnosis of community-acquired pneumonia in adults with acute cough. Am J Med. 2004;116(8): 529-535.
17. Ukena C, Mahfoud F, Kindermann M, Kindermann I, Bals R, Voors AA, van Veldhuisen DJ, Böhm M. The cardiopulmonary continuum systemic inflammation as 'common soil' of heart and lung disease. Int J Cardiol. 2010;145(2): 172-176.
18. Peng C, Tian C, Zhang Y, Yang X, Feng Y, Fan H. C-reactive protein levels predict bacterial exacerbation in patients with chronic obstructive pulmonary disease. Am J Med Sci. 2013;345(3): 190-194.
19. Jacobsen SK, Weis N, Almdal T. Use of antibiotics in patients admitted to the hospital due to acute exacerbation of chronic obstructive pulmonary disease (COPD). Eur J Intern Med. 2002;13(8): 514-517.
20. Johannessen A, Omenaas ER, Bakke PS, Gulsvik A. Implications of reversibility testing on prevalence and risk factors for chronic obstructive pulmonary disease: a community study. Thorax. 2005;60(10): 842-847.
21. Rabbat A, Guetta A, Lorut C, Lefebvre A, Roche N, Huchon G. [Management of acute exacerbations of COPD]. Rev Mal Respir. 2010;27(8): 939-953.
22. Schonhofer B. [Non-invasive ventilation in the treatment of acute respiratory and chronic ventilatory failure]. Dtsch Med Wochenschr. 2009;134(11): 530-535.